Author

G. Golino

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Approach:experimental assay· 4 Organism:human· 4 Research Focus:cancer & tumor microenvironment· 2 Research Focus:host-pathogen & immune response· 2 Research Focus:benchmarking· 1 Assay:bulk RNA-seq· 1

Frequent Co-Authors

A. Stathis· 4 shared C. Tarantelli· 4 shared E. Gaudio· 4 shared E. Zucca· 4 shared F. Bertoni· 4 shared F. Spriano· 4 shared L. Cascione· 4 shared A. J. Arribas· 3 shared

Activity by Year

2022-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 44 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

A. Stathis

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Targeting CD19-positive lymphomas with the antibody-drug conjugate (ADC) loncastuximab tesirine: preclinical evidence as single agent and as combinatorial approach

C. Tarantelli, D. Wald, N. Munz, F. Spriano, A. Bruscaggin, E. Cannas, L. Cascione, E. Gaudio, A. J. Arribas, S. Manjappa, G. Golino, L. Scalise, E. Zucca, A. Stathis, P. H. Van Berkel, , F. Bertoni

This study evaluates the efficacy of the anti-CD19 ADC loncastuximab tesirine as a single agent and in combination with other therapies against lymphomas.

bioRxiv · Aug 17, 2023 · PreprintCancer Biology

Targeting CD25-positive lymphoma cells with the antibody-drug conjugate camidanlumab tesirine as single agent or in combination with targeted agents

F. Spriano, C. Tarantelli, L. Cascione, E. Gaudio, G. Golino, L. Scalise, E. Zucca, A. Stathis, P. H. Van Berkel, F. Zammarchi, F. Bertoni

This study evaluates the anti-lymphoma activity of camidanlumab tesirine as a single agent and in combination with targeted agents in various lymphoma cell lines.

bioRxiv · Jul 2, 2023Cancer Biology

The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib

G. Sartori, C. Tarantelli, F. Spriano, E. Gaudio, L. Cascione, M. Mascia, M. Barreca, A. J. Arribas, L. Licenziato, G. Golino, A. Ferragamo, S. Pileri, G. Damia, E. Zucca, A. Stathis, , F. Bertoni

This paper shows that elimusertib, an ATR inhibitor, has anti-lymphoma activity and synergizes with copanlisib, a PI3K inhibitor, in multiple lymphoma models.

bioRxiv · Feb 10, 2023Cancer Biology

A first-in-class Wiskott-Aldrich syndrome protein (WASp) activator with anti-tumor activity in hematological cancers

F. Spriano, G. Sartori, L. Barnabei, A. J. Arribas, M. Guala, A. M. Carrasco del Amor, M. R. Tomasso, C. Tarantelli, L. Cascione, G. Golino, M. E. Riveiro, R. Bortolozzi, A. Lupia, F. Paduano, S. Huguet, , E. Gaudio

This paper develops EG-011, a first-in-class WASp activator with anti-tumor activity in hematological cancers, including resistant models.

bioRxiv · Nov 25, 2022 · PreprintCancer Biology